Cellebrite wird am 13. August 2026 die Finanzergebnisse für das zweite Quartal 2026 bekannt geben

This is a catalyst, not a thesis change. For CLBT, the market reaction will hinge less on the reported quarter and more on whether management confirms that public-sector deal cycles are still shortening and that cloud mix is pulling gross margin higher; those are the two levers that can justify multiple expansion in a name this small. If either bookings or FY26 guide softens, the stock can de-rate quickly because the base case already assumes persistent growth and some operating leverage.

The important second-order effect is competitive positioning versus other govtech/security workflows: a clean print would reinforce that digital evidence management is still budget-resilient even as agencies delay broader IT spend, which would be constructive for adjacent names with exposure to law-enforcement, compliance, and data handling workflows. Conversely, if procurement slows, it would be an early warning for the broader public-safety software stack, not just CLBT, because these buyers often move in sync on annual budget windows.

Near term, the event is likely to trade on guidance credibility rather than the quarter itself. Over 1-3 months, the key falsifier is any downgrade to full-year revenue growth or margin expansion; over 6-18 months, the bull case breaks if the company cannot convert AI/automation claims into sustained RPO and cash flow conversion. Consensus may be underweighting how much of CLBT is really a budget-cycle story, not a generic cybersecurity story, which means any sympathy trade with broader cyber ETFs could be overstated.

Given the low-impact setup, the best edge may be to wait for the print rather than force a position. If the stock rallies into earnings and implied move is rich, a tactical call spread sale could capture event premium; if it sells off on a guide miss but remains above pre-earnings levels after the call, that is the more attractive entry for a medium-term long.